New drugs, new challenges for dermatologists: mucocutaneous ulcers secondary to everolimus

AUTOR(ES)

Pasin, Victor Pavan, Pereira, Amanda Regio, Carvalho, Kalline Andrade de, Paiva, João Marcos Góes de, Enokihara, Milvia Maria Simões e Silva, Porro, Adriana Maria

FONTE

An. Bras. Dermatol.

DATA DE PUBLICAÇÃO

2015-06

RESUMO

AbstractEverolimus, a mammalian target of rapamycin inhibitor, is an emerging drug, which is being increasingly applied in oncology and solid organ transplantation. Oral ulcers are a frequent side effect associated with this immunosupressor. We report the case of a renal transplant recipient who developed disfiguring oral and perianal ulcers secondary to everolimus's toxicity. This is probably the first report of perianal involvement. Dermatologists need to be aware of the potential mucocutaneous adverse effects related to these new drugs that are becoming evermore common in our clinical practice.

Documentos Relacionados

• Polymer-Based Sustained-Release Dosage Forms for Protein Drugs, Challenges, and Recent Advances
• “New approach” as Health Canada seeks conditional licences for drugs, new pediatric office
• New interventional procedures: Unlike drugs, are implemented despite paucity of evidence
• Antieplleptic Drugs, fourth edition
• Neurotransmitters and Drugs, Second Ed